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ABSTRACT
Background    Retroperitoneal liposarcoma (RL) is 
a relatively rare tumor and is usually found at the ad-
vanced stage. Chemotherapy or radiotherapy for this 
tumor is not yet defined, and if operable, surgery is the 
treatment of choice. Complete resection of tumor with 
wide margins including excision of other organs has 
been recommended. However, many patients suffer from 
deterioration of the quality of a postoperative life. In the 
present study, we retrospectively analyzed the ideal sur-
gical procedures for treating RL.
Methods    RL patients treated at our institute between 
2003 and 2013 amounted to 10. RL was primary in 5 
patients and recurrent in the rest 5. We analyzed cases of 
the 10 patients retrospectively.
Results    Tumor resection was performed for 9 patients, 
7 of whom underwent complete tumor resection. RL was 
well-differentiated in 6 patients and dedifferentiated in 4. 
We analyzed the overall survival of 10 patients, and the 
relapse free survival of the operated 9 patients. Patients 
with well-differentiated RL showed better survival than 
those with dedifferentiated RL. Even the recurrent RL 
was huge, complete tumor resection could be performed 
in the well-differentiated type, but it was difficult in the 
dedifferentiated type.  
Conclusion    In the recurrent huge RL, the chance of a 
margin-negative resection remains low, but surgery re-
mains the treatment of choice. Tumor resection with pre-
serving important organs may improve patients’ quality 
of postoperative life and survival. 
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Retroperitoneal sarcomas are relatively rare. Among 
them, liposarcoma is one of the most common subtypes. 
Retroperitoneal liposarcoma (RL) is classified into 5 
subtypes according to the World Health Organization 
Classification: well-differentiated, dedifferentiated, myx-
oid/round cell, pleomorphic and mixed-type.1 The peak 
incidence is in the 6th decade of life2 and the incidence 
is almost equal in men and women with a slight male 
predominance.3
 RL is often asymptomatic and considerably large 
when initially diagnosed. Complete resection for cura-
tive intent is the treatment of choice, and a negative 
margin should be achieved to improve survival, even if 
resection of adjacent organs is needed.4–8 But, the results 
of surgery for RL have been quite inferior to those of ex-
tremity sarcomas because of the large size at operation 
and difficulty in resecting the tumor due to its anatomi-
cal location. Furthermore, many patients suffer from 
high frequency of local recurrence of tumor after such 
radical and complete operation. Neoadjuvant and adju-
vant treatments with chemotherapy or radiotherapy have 
also not shown any consistent benefit.9, 10 This paper 
shows the surgical treatment results and prognosis of RL 
in a single institute of Japan.
 
MATERIALS AND METHODS
Between 2003 and 2013, a total of 5,590 patients vis-
ited our institute. Retroperitoneal tumors were detected 
in 43 patients (0.8%). Among them, 10 patients (10/43, 
23.3%) had RL. Also, malignant fibrous histiocytomas 
and leiomyosarcomas were found in 10 and 7 patients, 
respectively, and metastatic tumors, in 3. Recent findings 
on the genetic field suggest that most lesions diagnosed 
as malignant fibrous histiocytomas are in fact dedif-
ferentiated liposarcomas.11, 12 However, diagnosis of 
disease known as malignant fibrous histiocytoma is not 
esablished now. Thus, in the present study, we registered 
only the tumors histologically proved to be liposarcoma.
 The patients’ records, operative notes, histopatho-
logical reports and imaging studies were reviewed 
retrospectively. Tumor size and tumor invasion were 
visualized by enhanced computed tomography and/or 
magnetic resonance imaging. Clinicopathological char-
acteristics, treatment procedures and prognoses were 
analyzed in the 10 patients.
 
RESULTS
Patients’ characteristics are indicated in Table 1. On vis-
iting our department, 5 patients had primary lesions, and 
another 5, recurrent lesions. Well-differentiated RL was 
detected in 6 patients, and dedifferentiated RL, in 4. 
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 The follow-up period of patients ranged from 3 to 
164 months. The mean survival time of 10 patients with 
RL was 155 months, and that of 6 patients with well-
differentiated RL (157 months) was significantly longer 
than that of 4 with dedifferentiated RL (135 months) 
(P = 0.027, Fig. 1). 
 Operation (resection of RL) was performed for 9 pa-
tients, but tumor resection was avoided for 1 patient be-
cause of tumor invasion to the greater psoas muscle and 
lumbar bone. The 9 patients had received tumor resec-
tions for the average of 3 times (range: 2–10 times). At 
the initial operation, complete tumor resection was per-
formed for 7 patients, but incomplete tumor resection for 
the rest 2 due to tumor invasion to neighboring organs. 
The average time interval between the initial resection 
and the 2nd (relapse free survival) in the 9 patients was 
54 months (range: 9–114 months). The mean relapse free 
survival of 6 patients with well-differentiated RL (64 
months) was longer than that of the rest 3 with dedif-
ferentiated RL (28 months), but the difference was not 
significant (P = 0.27, Fig. 2). 
 The following is the course of disease with the op-
eration procedures for recent cases of 2 patients with 
recurrent RL. Patient 1 was a 53-year-old female. About 
10 years ago, she underwent complete resection for well-
differentiated RL at a hospital. Thereafter, huge recur-
rent RL took place, which was resected 1 year ago at an-
other hospital. But, because the tumor involved the left 
ureter and the left external iliac artery, the operation was 
done with incomplete extraction of the tumor. According 
to the rapid growth of the residual tumor, she was ad-
mitted to our institute. Abdominal enhanced computed 
tomography indicated dislocation of the left ureter and 
the left external iliac artery due to tumor invasion. Also, 
Fig. 1. Overall survival of 6 patients with well-differentiated RL 
(solid line) is significantly better than that of 4 patients with dedif-
ferentiated RL (dotted line, P = 0.027). RL, retroperitoneal lipo-
sarcoma. 
Fig. 2. Relapse free survival of 6 patients with well-differentiated 
RL (solid line) is better than that of 3 patients with dedifferentiated 
type (dotted line), but the difference was not significant (P = 0.27). 
RL, retroperitoneal liposarcoma.
Table 1. Demographic details of 10 patients with retro-
peritoneal liposarcom (RL)
Age at initial diagnosis, mean (range), yr 57.5 (44–73)
Sex Male/female  1/9
Variant Well-differentiated  6
 Dedifferentiated  4
 Myxoid/round cell  0
 Pleomorphic  0
 Mixed type  0
Cases Primary/recurrent  5/5
Complete tumor resection  7
 Primary cases  3/5
 Recurrent cases  4/5
tumor invasion to the left iliopsoas muscle was observed 
(Fig. 3). At the time of operation, we found a huge tumor 
occupying almost the whole abdominal cavity (Fig. 4). 
At first, we inserted bilateral ureter stents, preserving 
the bilateral common iliac arteries and veins, bilateral 
internal and external iliac arteries and veins pulse bi-
lateral ureters, and performed complete extraction of 
the tumor. The extracted tumor weighed 6,500 g, the 
operation time was 9.5 h and the amount of intraopera-
tive bleeding was 2,820 mL. Patient 2 was a 65-year-old 
female. She underwent incomplete resection of dedif-
ferentiated RL at a hospital 2 years ago, because tumor 
invaded to bilateral ureters and bilateral iliac arteries 
and veins. But, the residual tumor enlarged gradually 
and she was moved to our institute. For this patient also, 
bilateral ureter stents were inserted at first. Almost the 
whole tumor was extracted with resection of the left in-
ternal iliac artery and vein. However, the tumor invaded 
to the inferior vena cava deeply, incomplete extraction 
was partly done. The extracted tumor weighed 6,000 g, 
operation time was 12.5 h and the intraoperative bleed-
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Fig. 3. Abdominal enhanced computed tomography indicates 
dislocation of the left ureter and the left external iliac artery due to 
tumor invasion. 
Fig. 4. The huge tumor occupies the whole abdominal cavity. 
Fig. 5. Complete resection of tumor with preserving important 
organs was performed. 
ing amount in Patient 2 was 2,590 mL. In each of the 2 
patients, even though a huge tumor involved important 
organs such as ureter and external iliac artery and vein, 
we could perform careful and prudent operation which 
led complete tumor extraction with preserving important 
organs.
 
DISCUSSION
Since RL has no characteristic symptom, patients often 
enter hospital with a very huge RL. Complete resection 
of RL with a surrounding margin of normal tissue is the 
only way to cure the patients, because the effectiveness 
of radiotherapy and chemotherapy for RL has not been 
established. A few retrospective studies reported that 
patients who had received adjuvant radiotherapy had a 
significant improvement in local failure free survival 
compared to patients who underwent surgery alone.13, 
14 On the other hand, Ballo et al.15 found no benefits 
from radiotherapy for RL. Moreover, they emphasized 
that a significant amount of toxicities of radiotherapy 
causes neuropathy, hydronephrosis, ureteral fistula and 
bowel obstruction. Thus, we have to consider that radio-
therapy to the retroperitoneum is challenging because 
of the large field size and presence of important visceral 
structures like the kidney, liver, bowels and spinal cord. 
Also, few retrospective and prospective studies indicated 
that neoadjuvant or adjuvant chemotherapy showed the 
survival benefit of patients with RL. Moreover, they 
concluded that chemotherapy worsened the performance 
status of the patients.16, 17  
 To achieve a negative margin depends on the rela-
tion of tumor to major vascular structures and to inva-
sion of adjacent visceral organs. Complete resection 
rates in several series for primary RL vary from 43% to 
95%.18–21 The rate will be worse in patients with recur-
rent huge RL. In our series, the complete resection rate 
of primary RL was 78%. To achieve a negative margin, 
Kumar et al.22 recommended combined resection of one 
or more organs abutting the tumor such as kidney, colon, 
adrenals, spleen and pancreas rather than peeling off 
the organ from the tumor. But we know that many RL 
patients who underwent combined resection suffer from 
conditions lacking important organs. Moreover, huge RL 
often involves inferior vena cava, abdominal aorta, com-
mon ileac artery or vein, or bilateral ureters. For such 
patients, peeling off technique should be recommended 
to preserve the important organs.
 The well-differentiated liposarcomas grow slowly, 
but dedifferentiated sarcomas grow faster and have a 
higher ability to metastasize than well-differentiated 
liposarcomas. We found that well-differentiated RL 
had better outcomes in terms of recurrence, rate of me-
tastasis and overall survival than dedifferentiated RL. 
Moreover, considerable attention is paid to the observa-
tion that well-differentiated liposarcoma may convert to 
dedifferentiated liposarcoma after one or more recur-
Left ureter
Left common ileac artery
Left psoas muscle
Left external ileac artery
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rences.23, 24 In the present study, we found that dediffer-
entiated RL more hardly invaded to neighboring organs 
(aorta, vena cava or ureter) than well-differentiated RL. 
So, the peeling off operation was more difficult in dedif-
ferentiated RL. 
 Local recurrence of RL after surgery is frequent and 
the rate was reported from 50% to 85%.25, 26 RL recurs 
in a huge form, but surgery remains the treatment of 
choice. Although the chance of a margin-negative resec-
tion remains low, adequate resection is associated with 
an improved survival and hence surgery is preferred for 
recurrent disease. Also, we can consider adjuvant radio-
therapy to improve the relapse free survival of patients 
with recurrent RL. Radiotherapy to the retroperitoneum 
is challenging and the radiation dose should be in mini-
mum to avoid the risk of radiation injury. 
The authors declare no conflict of interest.
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